| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/07/2013 | US20130296398 Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy |
| 11/07/2013 | US20130296386 Small molecule rnase inhibitors and methods of use |
| 11/07/2013 | US20130296382 Non-nucleoside reverse transcriptase inhibitors |
| 11/07/2013 | US20130296380 Novel Ureas for the Treatment and Prevention of Cancer |
| 11/07/2013 | US20130296379 Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid |
| 11/07/2013 | US20130296378 Triazole compounds that modulate hsp90 activity |
| 11/07/2013 | US20130296377 Complement pathway modulators and uses thereof |
| 11/07/2013 | US20130296364 Modulators of atp-binding cassette-transporters |
| 11/07/2013 | US20130296363 Quinoline and isoquinoline derivatives for use as jak modulators |
| 11/07/2013 | US20130296362 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 11/07/2013 | US20130296359 Treatment of solid tumors with rapamycin derivatives |
| 11/07/2013 | US20130296351 2-Thiopyrimidinones |
| 11/07/2013 | US20130296347 Compositions and Methods for Prophylaxis and Treatment of Addictions |
| 11/07/2013 | US20130296336 5-ht1a receptor subtype agonist |
| 11/07/2013 | US20130296330 Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus |
| 11/07/2013 | US20130296327 Substituted heterocylic compounds |
| 11/07/2013 | US20130296324 Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment |
| 11/07/2013 | US20130296322 Serotonin reuptake inhibitors |
| 11/07/2013 | US20130296318 Compounds and compositions as protein kinase inhibitors |
| 11/07/2013 | US20130296314 Gastric and colonic formulations and methods for making and using them |
| 11/07/2013 | US20130296309 Aryl pyridine as aldosterone synthase inhibitors |
| 11/07/2013 | US20130296305 Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
| 11/07/2013 | US20130296303 Spiro-oxindole mdm2 antagonists |
| 11/07/2013 | US20130296300 Quinolines and aza-quinolines as crth2 receptor modulators |
| 11/07/2013 | US20130296295 Bcl-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 11/07/2013 | US20130296282 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis |
| 11/07/2013 | US20130296274 Pyrrolidinones as metap-2 inhibitors |
| 11/07/2013 | US20130296248 Methods of Treating Depression and Other Related Diseases |
| 11/07/2013 | US20130296237 Use Of Chloroquine To Treat Metabolic Syndrome |
| 11/07/2013 | US20130296223 Use of thymosin alpha for the treatment of sepsis |
| 11/07/2013 | US20130295196 Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof |
| 11/07/2013 | US20130295185 Compounds and methods for inducing apoptosis in cancer cells using a bh3 alpha-helical mimetic |
| 11/07/2013 | US20130295179 Novel omega-3 and omega-6 fatty acid compositions and uses thereof |
| 11/07/2013 | US20130295158 Composition for the transdermal delivery of fentanyl |
| 11/07/2013 | US20130295141 Matrix metalloproteinase inhibitors |
| 11/07/2013 | US20130295122 Elastin digest compositions and methods utilizing same |
| 11/07/2013 | US20130295119 Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof |
| 11/07/2013 | US20130295117 Aldosterone induced elastin production |
| 11/07/2013 | US20130295106 Frizzled-Binding Agents And Uses Thereof |
| 11/07/2013 | US20130295105 Frizzled-binding agents and uses thereof |
| 11/07/2013 | US20130295097 Human Antibodies to Fel d1 and Methods of Use Thereof |
| 11/07/2013 | US20130295092 Method for the Treatment of Neurodegenerative Diseases |
| 11/07/2013 | US20130295089 Method of promoting bone growth by an anti-actriia antibody |
| 11/07/2013 | US20130295088 Methods of treating inflammatory pain |
| 11/07/2013 | US20130295087 Methods of treating chronic pain |
| 11/07/2013 | US20130295083 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes |
| 11/07/2013 | US20130295078 Method of improving absorption of vitamin e by a pet animal |
| 11/07/2013 | US20130295075 Compositions and methods of treating glaucoma |
| 11/07/2013 | US20130295074 Pyridoxamine for the Treatment of Diabetic Kidney Disease |
| 11/07/2013 | US20130295051 Novel compounds and compositions for the inhibition of nampt |
| 11/07/2013 | US20130295050 Anti-igf-i receptor antibodies, dnas, vectors, host cells and genetic constructs |
| 11/07/2013 | US20130295049 Linked dibenzimidazole antivirals |
| 11/07/2013 | US20130295048 Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor |
| 11/07/2013 | US20130295045 Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| 11/07/2013 | US20130295043 Vaccination in elderly patients |
| 11/07/2013 | US20130295042 Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease |
| 11/07/2013 | US20130295025 Use of beta-adrenergic inverse agonists for smoking cessation |
| 11/07/2013 | US20130295022 Moisturizing Foam Containing Lanolin |
| 11/07/2013 | US20130295007 Anti-pmel17 antibodies and immunoconjugates |
| 11/07/2013 | US20130295004 Il-1 binding proteins |
| 11/06/2013 | EP2659933A1 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. |
| 11/06/2013 | EP2659910A1 Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells |
| 11/06/2013 | EP2659896A2 Electricity-generating particulates and the use thereof |
| 11/06/2013 | EP2659885A1 Hepatitis C Antiviral Compositions and Methods |
| 11/06/2013 | EP2659773A1 Improved tissue maintenance |
| 11/06/2013 | EP2658540A1 Therapeutic use of dimiracetam to prevent the hand&foot syndrome caused by sorafenib |
| 11/06/2013 | EP2658539A2 Composition for prevention of nausea or vomiting |
| 11/06/2013 | EP2658533A2 Combination of components for the prevention and treatment of frailty |
| 11/06/2013 | EP2658523A1 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease |
| 11/06/2013 | EP1854454B1 Method for the preparation of amorphous telmisartan |
| 11/06/2013 | CN103384520A Combination of components for the prevention and treatment of frailty |
| 11/06/2013 | CN103384519A Anti-microbial composition |
| 11/06/2013 | CN103381271A Triazol compounds for treating biofilm formation |
| 11/06/2013 | CN103381270A Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction |
| 11/06/2013 | CN103381269A Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents |
| 11/06/2013 | CN103381268A Solid pharmaceutical composition including proton pump inhibitor |
| 11/06/2013 | CN102940884B Inhibitor for hepatoma carcinoma cell and application in aspect of inhibiting tumor growth thereof |
| 11/06/2013 | CN102716486B Slowly-releasing anticancer drug composition and application thereof |
| 11/06/2013 | CN102573813B 持续药物传递系统 Sustained drug delivery system |
| 11/06/2013 | CN102274347B Anticancer composition |
| 11/06/2013 | CN102245174B Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents |
| 11/06/2013 | CN102198150B Antitumor drug with double active components and application thereof |
| 11/06/2013 | CN101568350B Lipidized interferon and uses thereof |
| 11/06/2013 | CN101361723B Improved pharmaceutical compositions |
| 11/06/2013 | CN101267815B Metal-beta-lactamase inhibitor |
| 11/06/2013 | CN101134038B 缓释的口服给药组合物 The sustained-release composition for oral administration |
| 11/06/2013 | CN101073667B Enhancer for antibody to lymphocytic tumors |
| 11/05/2013 | US8575219 Compounds for the treatment of psychiatric or substance abuse disorders |
| 11/05/2013 | US8575088 Method of preventing acute or sub-acute hepatic failure by administering a long-acting recombinant human soluble tumor necrosis factor alpha receptor II fusion protein |
| 11/05/2013 | US8574909 Saccharomyces cerevisiae yeast strain with functional expression of a GLUT transporter gene |
| 11/05/2013 | US8574599 Methods and products for inducing mucosal immunity |
| 11/05/2013 | US8574569 Stabilized protease composition |
| 11/05/2013 | CA2690395C Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 11/05/2013 | CA2507811C Process for the determination of the primary structure of the messenger rna coding for the human recombinant endooligopeptidase a (heopa) [af217798] |
| 11/05/2013 | CA2461305C Methods of suppressing microglial activation and systemic inflammatory responses |
| 11/05/2013 | CA2394015C Tweak receptor |
| 10/31/2013 | WO2013163582A1 Fungal mycobiome as probiotics, diagnostics and therapeutics |
| 10/31/2013 | WO2013163219A1 Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
| 10/31/2013 | WO2013162027A1 Neuronal differentiation promoter |
| 10/31/2013 | WO2013162021A1 Prophylactic or therapeutic agent for hepatic diseases |